Auspex Pharmaceuticals, a clinical stage company developing next-generation medicines with improved safety and performance through the targeted deuteration of clinically validated drugs, today announced the appointment of Michael Grey as President and Chief Executive Officer and R. Gary Gilmore as Chief Financial Officer. Mr. Grey has also joined the company's board of directors.
"We are pleased to have Mike and Gary join the Auspex team," said Dr. Pratik Shah, the company's Chairman. "Mike's extensive experience and track record in building companies involved in drug discovery, development, and commercialization, along with Gary's many years as a senior corporate finance executive, will be invaluable in leading Auspex in the next phase of its development."
"Auspex has the earliest and broadest position on the application of deuteration technology to validated medicines and has built an attractive pipeline of promising drug candidates," said Mike Grey. "The lead program, SD-254, a Selective Serotonin-Norepinephrine Reuptake Inhibitor, has demonstrated in clinical trials an improved profile compared to Effexor XR, the leading treatment for depression. Auspex has demonstrated it can produce potential best-in-class drugs, while reducing the risk, time and cost of drug development, and I look forward to working with Gary and other members of the Auspex team to advance SD-254 and the rest of the pipeline."
Mike Grey has over 30 years experience in the pharmaceutical and biotechnology industries. Prior to Auspex, Mr. Grey was President and CEO of SGX Pharmaceuticals, which was recently acquired by Eli Lilly. Prior to joining SGX, Mr. Grey was President and CEO of Trega Biosciences, Inc., which was acquired by LION bioscience, AG. Prior to Trega, he was President of BioChem Therapeutic Inc., the pharmaceutical division of BioChem Pharma, Inc., and was President and Chief Operating Officer of Ansan, Inc., an early stage biopharmaceutical company. Previously, he served in various roles with Glaxo, including head of worldwide business development.
Gary Gilmore has over 20 years experience in corporate finance, including nearly 15 years as CFO. Before joining Auspex, Mr. Gilmore was CFO of Althea Technologies, Inc., a contract manufacturing organization servicing the pharmaceutical and biotechnology industries. Prior to Althea, he was CFO for Preventsys, Inc., which was acquired by McAfee. He was also CFO of Holocom Networks, Inc. and has provided extensive management consulting services to Fortune 500 companies and start-up organizations including Ligand Pharmaceuticals, AMCC, and Peregrine Systems.